Kory James Wentworth
CIK: 0001725663
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Entrada Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (26 total)
- Sep 2, 2026TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct1.7K shares at avg. $7.14$12K - Apr 1, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct2.5K shares at avg. $12.95$32K - Mar 10, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct11.4K shares at avg. $13.02$148K - Mar 9, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct5.1K shares at avg. $13.00$66K - Mar 4, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct8K shares at avg. $12.25$98K - Mar 3, 2026TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct5.7K shares at avg. $11.76$67K - Mar 2, 2026TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct2.9K shares at avg. $11.66$34K - Mar 1, 2026TRDA
Entrada Therapeutics, Inc.
Award(A)Direct44.6K shares- - Nov 21, 2025TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct8.9K shares at avg. $9.98$89K - Sep 2, 2025TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct1.7K shares at avg. $5.43$9K - Apr 3, 2025TRDA
Entrada Therapeutics, Inc.
Exercise(M)Direct11.1K shares at avg. $2.10$23K - Mar 17, 2025TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct1.8K shares at avg. $10.67$19K - Mar 3, 2025TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct4.9K shares at avg. $11.68$58K - Mar 1, 2025TRDA
Entrada Therapeutics, Inc.
Award(A)Direct42.4K shares- - Dec 2, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct5K shares at avg. $20.00$100K - Dec 2, 2024TRDA
Entrada Therapeutics, Inc.
Exercise(M)Direct5K shares at avg. $2.10$11K - Nov 29, 2024TRDA
Entrada Therapeutics, Inc.
Exercise(M)Direct1K shares at avg. $2.10$2K - Nov 29, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct1K shares at avg. $19.97$20K - Nov 11, 2024TRDA
Entrada Therapeutics, Inc.
Exercise(M)Direct6K shares at avg. $2.10$13K - Nov 11, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct8.6K shares at avg. $19.98$173K - Sep 9, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct3.2K shares at avg. $14.97$48K - Sep 5, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct165 shares at avg. $15.13$2K - Sep 4, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct941 shares at avg. $15.42$15K - Sep 3, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct462 shares at avg. $15.76$7K - Sep 3, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct14 shares at avg. $17.70$247.828
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 2, 2026 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 1,733 | $7.14 | $12,380 | Direct |
| Apr 1, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 2,500 | $12.95 | $32,375 | Direct |
| Mar 10, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 11,388 | $13.02 | $148,216 | Direct |
| Mar 9, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 5,089 | $13.00 | $66,163 | Direct |
| Mar 4, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 7,988 | $12.25 | $97,892 | Direct |
| Mar 3, 2026 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 5,712 | $11.76 | $67,153 | Direct |
| Mar 2, 2026 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 2,939 | $11.66 | $34,263 | Direct |
| Mar 1, 2026 | TRDA Entrada Therapeutics, Inc. | Award(A) | 44,600 | - | $0 | Direct |
| Nov 21, 2025 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 8,910 | $9.98 | $88,932 | Direct |
| Sep 2, 2025 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 1,734 | $5.43 | $9,416 | Direct |
| Apr 3, 2025 | TRDA Entrada Therapeutics, Inc. | Exercise(M) | 11,134 | $2.10 | $23,381 | Direct |
| Mar 17, 2025 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 1,784 | $10.67 | $19,035 | Direct |
| Mar 3, 2025 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 4,929 | $11.68 | $57,564 | Direct |
| Mar 1, 2025 | TRDA Entrada Therapeutics, Inc. | Award(A) | 42,400 | - | - | Direct |
| Dec 2, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 5,000 | $20.00 | $99,978 | Direct |
| Dec 2, 2024 | TRDA Entrada Therapeutics, Inc. | Exercise(M) | 5,000 | $2.10 | $10,500 | Direct |
| Nov 29, 2024 | TRDA Entrada Therapeutics, Inc. | Exercise(M) | 1,000 | $2.10 | $2,100 | Direct |
| Nov 29, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 1,000 | $19.97 | $19,970 | Direct |
| Nov 11, 2024 | TRDA Entrada Therapeutics, Inc. | Exercise(M) | 6,000 | $2.10 | $12,600 | Direct |
| Nov 11, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 8,637 | $19.98 | $172,562 | Direct |
| Sep 9, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 3,195 | $14.97 | $47,832 | Direct |
| Sep 5, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 165 | $15.13 | $2,496 | Direct |
| Sep 4, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 941 | $15.42 | $14,513 | Direct |
| Sep 3, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 462 | $15.76 | $7,282 | Direct |
| Sep 3, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 14 | $17.70 | $248 | Direct |
1-25 of 26 transactions
About WENTWORTH KORY JAMES
WENTWORTH KORY JAMES (SEC CIK 0001725663) files insider reports with the SEC as Chief Financial Officer of Entrada Therapeutics, Inc. (TRDA).
Signal8 holds 14 ownership filings by WENTWORTH KORY JAMES, all Form 4s, filed between Sep 5, 2024 and Sep 3, 2026. Those filings report 26 transactions, from Sep 3, 2024 to Sep 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on WENTWORTH KORY JAMES's filings is in BOSTON, MA.
Recent filings by WENTWORTH KORY JAMES
- Sep 2, 2026: Tax withholding of TRDA shares (Form 4, code F).
- Apr 1, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Mar 10, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Mar 9, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Mar 4, 2026: Open-market sale of TRDA shares (Form 4, code S).
Other insiders filing for Entrada Therapeutics, Inc. (TRDA)
- MPM BIOVENTURES 2018, L.P., 10% Owner
- MPM BioVentures 2014, L.P., 10% Owner
- Doshi Dipal, CEO
- Dowden Nathan J, President & COO
- Sethuraman Natarajan, President, Research & Develop.
- PARMAR KUSH, Director